{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-027568","form_type":"8-K","ticker":"AQST","cik":"0001398733","company_name":"Aquestive Therapeutics, Inc.","filed_at":"2022-11-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.448316+00:00","generated_at":"2026-06-22T17:45:43.698147+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aquestive reports Q3 2022 revenue $11.5M, net loss $12.5M; licensing deals and AQST-109 progress","bullets":["Total revenues $11.5M (down from $13.3M Q3 2021); net loss $12.5M ($0.23/share) vs $14.6M ($0.37) prior year.","Cash $18.6M; reaffirms FY2022 revenue guidance $46-49M and adjusted EBITDA loss $37-43M.","AQST-109 epinephrine film: positive EPIPHAST II data; FDA EoP2 meeting scheduled Q4 2022.","Licensing deals: Pharmanovia (Libervant EU/UK/MENA) $3.5M upfront; Otter/Assertio (Sympazan) $9M upfront + $6M milestone; Haisco (Exservan China) $7M upfront.","Appointed Dr. Kenneth Truitt as CMO; Timothy Morris to board; exploring out-licensing Libervant North America."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-027568","json":"https://secwatch.observer/filing/0001628280-22-027568.json","markdown":"https://secwatch.observer/filing/0001628280-22-027568.md","text":"https://secwatch.observer/filing/0001628280-22-027568.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1398733/000162828022027568/0001628280-22-027568-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1398733/000162828022027568/aqst-20221101.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T17:45:43.698147+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"6ff4b21bd206af106b91617fa2c83d17124d1931","claim":"Aquestive Therapeutics, Inc. updated its third quarter ended September 30, 2022 guidance (reaffirmed).","evidence_excerpt":"On November 1, 2022, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing its reported financial results for the third quarter ended September 30, 2022 and provided an update on recent developments in its business.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1398733/000162828022027568/0001628280-22-027568-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2022"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}